Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment

NCT05904730 is registered in ClinicalTrials.gov with Lynkcell Europe as lead sponsor.

NCT NCT05904730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
Lead sponsor
Lynkcell Europe
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2023
Completion date
December 26, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brca mutation, breast cancer, breast neoplasms, her-2 protein overexpression, her2-negative breast cancer, her2-positive breast cancer, ovarian cancer, ovarian neoplasms